Home
Healthcare
Healthcare & Pharmaceuticals
Idiopathic Gastroparesis Drugs Market Growth & Trends [2030]

Global Idiopathic Gastroparesis Drugs Market

Name: Growth Market Reports
Address: 500 East E Street, Ontario, 91764, USA
Telephone: +1 909 414 1393

Segments - By Drug (Antiemetic drugs, Prokinetic drugs, Others), By Route of Administration (Oral, Intravenous, Nasal, Transdermal), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies), and Region (North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2022-2030

HC-5065
4.3 Rating
213 Pages

09-03-2023
66 Reviews

Author :

Raksha Sharma

Fact-checked by :

Vineet Pandey

Editor :

Vishal Golekar

Report Description

Idiopathic Gastroparesis Drugs Market Outlook

The global idiopathic gastroparesis market was estimated at USD 1,192.7 Million in 2021 and is anticipated to reach USD 1,699.3 Million by 2030, expanding at a CAGR of 4.1% during the forecast period.

Gastroparesis is a chronic disorder of the stomach that affects the normal and spontaneous movement of the stomach and slows or stops the movement of food from stomach to small intestine. Idiopathic gastroparesis is one of the types of gastroparesis caused by unknown factors.

Gastroparesis occurs on account of damage to the vagus nerve due to injury or illness. It influences the unconstrained development of the stomach muscles. Gastroparesis interferes with normal digestion and causes nausea, vomiting, and abdominal pain.

Antiemetic and prokinetic drugs are commonly used drugs. Medications such as metoclopramide, domperidone, erythromycin, and others are used to treat the condition of idiopathic gastroparesis.

Macro-economic Factors

Government Regulations

Government regulations play an integral role in the approval and branding of gastroparesis drugs for the consumption and treatment of patients. Metoclopramide, a dopamine-2 receptor antagonist, is approved by the US Food and Drug Administration (FDA) for the treatment of gastroparesis. Presently, prucalopride is approved in some countries of Western Europe and in Canada for the management of chronic constipation, and it has the potential to treat symptoms of gastroparesis and delayed gastric emptying.

R&D Activities

Antiemetic and prokinetic drugs are emerging as a significant class of therapeutic agents for the treatment of idiopathic gastroparesis. The treatments available for the diseases are the outcome of previous R&D activities in the field of gastroparesis.

These R&D activities include various steps and perspectives consisting of participants, development phases, citations of related patents, and therapeutic indications with potentially valuable insights for pharmaceutical investors, researchers, and policymakers. R&D activities are a major factor affecting the overall gastroparesis market, the reasons for idiopathic gastroparesis are unknown.

Idiopathic Gastroparesis Drugs Market Dynamics

Market Driver - Increasing Prevalence of Gastroparesis Cases

Cases of gastroparesis are rising day by day. In majority of the cases, diabetes and post-surgical complications are the common origins for this disease. Presently, the cases of idiopathic gastroparesis are increasing, with the unavailability of patient history regarding diabetes or any post-surgical issues. Hence, doctors are prescribing antiemetic and prokinetic drugs for treating patients dealing with constipated state of stomach, abdominal pain, vomiting, and nausea. This factor is driving the market.

Market Driver - Rising approval of medications with different routes of administration

Idiopathic gastroparesis drugs are injected through various routes of administration, as these medications are available in various forms, such as tablets, injections, patches, and nasal medication. Oral tablets are a common form of medication for treating idiopathic gastroparesis. Availability of different forms of the drugs make it convenient for patients to receive the treatment, as the intravenous route of administration is extremely painful. This factor is projected to propel the market.

Market Restraint - Lack of awareness in underdeveloped countries

Idiopathic gastroparesis drugs are popular in developed countries as a treatment method for gastroparesis caused by unknown factors. These drugs are not adopted in underdeveloped countries, due to lack of awareness, low disposable income of people, and lack of knowledge of gastroenterology conditions.

A major part of the global population resides in countries such as China and India; however, the primary consumption of idiopathic gastroparesis is in North America and Europe. Lack of awareness regarding these drugs is expected to affect the growth of the idiopathic gastroparesis drugs market.

Market Opportunity- Increasing Focus on R&D activities by manufacturers

Various companies and research institutes are investing in research and development of gastroparesis drugs. This is expected to create lucrative opportunities for the market players. Increasing number of pipeline products and development of novel treatments are anticipated to create immense opportunities for the market growth during the forecast period. Various articles estimate the current prevalence of gastroparesis at 4% of the US population and rising diagnosis of idiopathic gastroparesis.

Scope of Idiopathic Gastroparesis Drugs Market Report

The report on the global idiopathic gastroparesis drugs market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes	Details
Report Title	Idiopathic Gastroparesis Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2021
Historic Data	2015 and 2020
Forecast Period	2022–2030
Segmentation	Drug (Antiemetic drugs, Prokinetic drugs, Other), Route of Administration (Oral, Intravenous, Nasal, Transdermal), Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered	EVOKE PHARMA, Cadila Pharmaceuticals, Janssen-Cilag Pty Limited, Abbott, ADVANZ PHARMA, iNova Pharmaceuticals, ANI Pharmaceuticals, Inc., AstraZeneca, Intas Pharmaceuticals Ltd., and Cipla Inc.

Idiopathic Gastroparesis Drugs Market Segmental Outlook

Based on drugs , the idiopathic gastroparesis drugs market is segmented into antiemetic drugs, prokinetic drugs, and others. The antiemetic drugs segment accounted for a significant market share during the forecast period. These drugs include metoclopramide, Zofran, prochlorperazine, and promethazine.

These drugs are used to treat gastrointestinal symptoms such as constipation, bloating, abdominal discomfort, and vomiting. It works by increasing the movements or contractions of the stomach and intestines. Easy availability, efficacy, high usage, and medication applicability in treating gastroparesis are major factors that are projected to boost the segment during the forecast period.

On the basis of route of administration, the idiopathic gastroparesis drugs market is segregated into oral, intravenous, nasal, and transdermal. The oral segment is expected to expand at a significant CAGR during the forecast period. Gastroparesis drugs include oral drugs such as ondansetron, Metoclopramide, and promethazine. These drugs help to reduce nausea and vomiting, which are common symptoms of gastroparesis. Oral medication is considered to be an effective treatment for gastroparesis.

Based on distribution channel, the idiopathic gastroparesis drugs market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to hold a large market share. Availability of various products is anticipated to propel the distribution channel segment during the forecast period.

Idiopathic Gastroparesis Drugs Market Regional Outlook

The market is divided into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America is projected to account for a significant share of the idiopathic gastroparesis drugs market during the forecast period, owing to the rising number of FDA approvals for gastroparesis drugs and high awareness about these drugs for therapeutic purposes.

Europe is expected to hold a substantial market share during the forecast period, owing to increasing R&D activities for patients with complicated and untreated gastroparesis condition.

The market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period, as underdeveloped countries are adopting the gastroparesis drugs treatment method for treating life-threatening gastric complications. Significant rise in the incidence of gastroenterology conditions is expected to boost the market

Key Benefits for Industry Participants & Stakeholders

In-depth Analysis of the Global Idiopathic Gastroparesis Drugs Market
Historical, Current, and Projected Market Size in terms of Value
Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
Industry Drivers, Restraints, and Opportunities Covered in the Study
Recent Industry Trends and Developments
Competitive Landscape & Strategies of Key Players
Neutral Perspective on Global Idiopathic Gastroparesis Drugs Market Performance

Segments

By Drug

Antiemetic drugs
Prokinetic drugs
Others

By Route of Administration

Oral
Intravenous
Nasal
Transdermal

By Distribution Channel

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

By Region

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Key Players

EVOKE PHARMA
Cadila Pharmaceuticals
Janssen-Cilag Pty Limited
Abbott
ADVANZ PHARMA
iNova Pharmaceuticals
ANI Pharmaceuticals, Inc.
AstraZeneca
Intas Pharmaceuticals Ltd.
Cipla Inc.

Competitive Landscape

Key players in the idiopathic gastroparesis drugs market include EVOKE PHARMA, Cadila Pharmaceuticals, Janssen-Cilag Pty Limited, Abbott, ADVANZ PHARMA, iNova Pharmaceuticals, ANI Pharmaceuticals, Inc., AstraZeneca, Intas Pharmaceuticals Ltd., and Cipla Inc.
Market players are pursuing key strategies such as acquisitions, collaborations, and geographic expansion, which is creating opportunities in the idiopathic gastroparesis drugs market.

Table Of Content

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Idiopathic Gastroparesis Drugs Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Idiopathic Gastroparesis Drugs Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Idiopathic Gastroparesis Drugs Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Idiopathic Gastroparesis Drugs Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Idiopathic Gastroparesis Drugs Market Size & Forecast, 2015-2030
      4.5.1 Idiopathic Gastroparesis Drugs Market Size and Y-o-Y Growth
      4.5.2 Idiopathic Gastroparesis Drugs Market Absolute $ Opportunity
   4.6 Regulations and Compliances: Gastroparesis Drugs Market
   4.7 Comparative Analysis: Diabetic v/s Idiopathic v/s Surgical Gastroparesis
Chapter 5 Global Idiopathic Gastroparesis Drugs Market Analysis and Forecast By Drug Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Drug Type
      5.1.2 Basis Point Share (BPS) Analysis By Drug Type
      5.1.3 Absolute $ Opportunity Assessment By Drug Type
   5.2 Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
      5.2.1 Antiemetic drugs
      5.2.2 Prokinetic drugs
      5.2.3 Others
   5.3 Market Attractiveness Analysis By Drug Type
Chapter 6 Global Idiopathic Gastroparesis Drugs Market Analysis and Forecast By Route of Administration
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Route of Administration
      6.1.2 Basis Point Share (BPS) Analysis By Route of Administration
      6.1.3 Absolute $ Opportunity Assessment By Route of Administration
   6.2 Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
      6.2.1 Oral
      6.2.2 Intravenous
      6.2.3 Nasal
      6.2.4 Transdermal
   6.3 Market Attractiveness Analysis By Route of Administration
Chapter 7 Global Idiopathic Gastroparesis Drugs Market Analysis and Forecast By Distribution Channel
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By Distribution Channel
      7.1.2 Basis Point Share (BPS) Analysis By Distribution Channel
      7.1.3 Absolute $ Opportunity Assessment By Distribution Channel
   7.2 Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
      7.2.1 Online Pharmacies
      7.2.2 Hospital Pharmacies
      7.2.3 Retail Pharmacies
   7.3 Market Attractiveness Analysis By Distribution Channel

Chapter 8 Global Idiopathic Gastroparesis Drugs Market Analysis and Forecast by Region
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities by Region
      8.1.2 Basis Point Share (BPS) Analysis by Region
      8.1.3 Absolute $ Opportunity Assessment by Region
   8.2 Idiopathic Gastroparesis Drugs Market Size Forecast by Region
      8.2.1 North America
      8.2.2 Europe
      8.2.3 Asia Pacific
      8.2.4 Latin America
      8.2.5 Middle East & Africa (MEA)
   8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
   9.1 Introduction
   9.2 Current & Future Impact Analysis
   9.3 Economic Impact Analysis
   9.4 Government Policies
   9.5 Investment Scenario
Chapter 10 North America Idiopathic Gastroparesis Drugs Analysis and Forecast
   10.1 Introduction
   10.2 North America Idiopathic Gastroparesis Drugs Market Size Forecast by Country
      10.2.1 U.S.
      10.2.2 Canada
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 North America Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
      10.6.1 Antiemetic drugs
      10.6.2 Prokinetic drugs
      10.6.3 Others
   10.7 Basis Point Share (BPS) Analysis By Drug Type
   10.8 Absolute $ Opportunity Assessment By Drug Type
   10.9 Market Attractiveness Analysis By Drug Type
   10.10 North America Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
      10.10.1 Oral
      10.10.2 Intravenous
      10.10.3 Nasal
      10.10.4 Transdermal
   10.11 Basis Point Share (BPS) Analysis By Route of Administration
   10.12 Absolute $ Opportunity Assessment By Route of Administration
   10.13 Market Attractiveness Analysis By Route of Administration
   10.14 North America Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
      10.14.1 Online Pharmacies
      10.14.2 Hospital Pharmacies
      10.14.3 Retail Pharmacies
   10.15 Basis Point Share (BPS) Analysis By Distribution Channel
   10.16 Absolute $ Opportunity Assessment By Distribution Channel
   10.17 Market Attractiveness Analysis By Distribution Channel
Chapter 11 Europe Idiopathic Gastroparesis Drugs Analysis and Forecast
   11.1 Introduction
   11.2 Europe Idiopathic Gastroparesis Drugs Market Size Forecast by Country
      11.2.1 Germany
      11.2.2 France
      11.2.3 Italy
      11.2.4 U.K.
      11.2.5 Spain
      11.2.6 Russia
      11.2.7 Rest of Europe
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Europe Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
      11.6.1 Antiemetic drugs
      11.6.2 Prokinetic drugs
      11.6.3 Others
   11.7 Basis Point Share (BPS) Analysis By Drug Type
   11.8 Absolute $ Opportunity Assessment By Drug Type
   11.9 Market Attractiveness Analysis By Drug Type
   11.10 Europe Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
      11.10.1 Oral
      11.10.2 Intravenous
      11.10.3 Nasal
      11.10.4 Transdermal
   11.11 Basis Point Share (BPS) Analysis By Route of Administration
   11.12 Absolute $ Opportunity Assessment By Route of Administration
   11.13 Market Attractiveness Analysis By Route of Administration
   11.14 Europe Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
      11.14.1 Online Pharmacies
      11.14.2 Hospital Pharmacies
      11.14.3 Retail Pharmacies
   11.15 Basis Point Share (BPS) Analysis By Distribution Channel
   11.16 Absolute $ Opportunity Assessment By Distribution Channel
   11.17 Market Attractiveness Analysis By Distribution Channel
Chapter 12 Asia Pacific Idiopathic Gastroparesis Drugs Analysis and Forecast
   12.1 Introduction
   12.2 Asia Pacific Idiopathic Gastroparesis Drugs Market Size Forecast by Country
      12.2.1 China
      12.2.2 Japan
      12.2.3 South Korea
      12.2.4 India
      12.2.5 Australia
      12.2.6 South East Asia (SEA)
      12.2.7 Rest of Asia Pacific (APAC)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Asia Pacific Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
      12.6.1 Antiemetic drugs
      12.6.2 Prokinetic drugs
      12.6.3 Others
   12.7 Basis Point Share (BPS) Analysis By Drug Type
   12.8 Absolute $ Opportunity Assessment By Drug Type
   12.9 Market Attractiveness Analysis By Drug Type
   12.10 Asia Pacific Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
      12.10.1 Oral
      12.10.2 Intravenous
      12.10.3 Nasal
      12.10.4 Transdermal
   12.11 Basis Point Share (BPS) Analysis By Route of Administration
   12.12 Absolute $ Opportunity Assessment By Route of Administration
   12.13 Market Attractiveness Analysis By Route of Administration
   12.14 Asia Pacific Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
      12.14.1 Online Pharmacies
      12.14.2 Hospital Pharmacies
      12.14.3 Retail Pharmacies
   12.15 Basis Point Share (BPS) Analysis By Distribution Channel
   12.16 Absolute $ Opportunity Assessment By Distribution Channel
   12.17 Market Attractiveness Analysis By Distribution Channel
Chapter 13 Latin America Idiopathic Gastroparesis Drugs Analysis and Forecast
   13.1 Introduction
   13.2 Latin America Idiopathic Gastroparesis Drugs Market Size Forecast by Country
      13.2.1 Brazil
      13.2.2 Mexico
      13.2.3 Rest of Latin America (LATAM)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Latin America Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
      13.6.1 Antiemetic drugs
      13.6.2 Prokinetic drugs
      13.6.3 Others
   13.7 Basis Point Share (BPS) Analysis By Drug Type
   13.8 Absolute $ Opportunity Assessment By Drug Type
   13.9 Market Attractiveness Analysis By Drug Type
   13.10 Latin America Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
      13.10.1 Oral
      13.10.2 Intravenous
      13.10.3 Nasal
      13.10.4 Transdermal
   13.11 Basis Point Share (BPS) Analysis By Route of Administration
   13.12 Absolute $ Opportunity Assessment By Route of Administration
   13.13 Market Attractiveness Analysis By Route of Administration
   13.14 Latin America Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
      13.14.1 Online Pharmacies
      13.14.2 Hospital Pharmacies
      13.14.3 Retail Pharmacies
   13.15 Basis Point Share (BPS) Analysis By Distribution Channel
   13.16 Absolute $ Opportunity Assessment By Distribution Channel
   13.17 Market Attractiveness Analysis By Distribution Channel
Chapter 14 Middle East & Africa (MEA) Idiopathic Gastroparesis Drugs Analysis and Forecast
   14.1 Introduction
   14.2 Middle East & Africa (MEA) Idiopathic Gastroparesis Drugs Market Size Forecast by Country
      14.2.1 Saudi Arabia
      14.2.2 South Africa
      14.2.3 UAE
      14.2.4 Rest of Middle East & Africa (MEA)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Middle East & Africa (MEA) Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
      14.6.1 Antiemetic drugs
      14.6.2 Prokinetic drugs
      14.6.3 Others
   14.7 Basis Point Share (BPS) Analysis By Drug Type
   14.8 Absolute $ Opportunity Assessment By Drug Type
   14.9 Market Attractiveness Analysis By Drug Type
   14.10 Middle East & Africa (MEA) Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
      14.10.1 Oral
      14.10.2 Intravenous
      14.10.3 Nasal
      14.10.4 Transdermal
   14.11 Basis Point Share (BPS) Analysis By Route of Administration
   14.12 Absolute $ Opportunity Assessment By Route of Administration
   14.13 Market Attractiveness Analysis By Route of Administration
   14.14 Middle East & Africa (MEA) Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
      14.14.1 Online Pharmacies
      14.14.2 Hospital Pharmacies
      14.14.3 Retail Pharmacies
   14.15 Basis Point Share (BPS) Analysis By Distribution Channel
   14.16 Absolute $ Opportunity Assessment By Distribution Channel
   14.17 Market Attractiveness Analysis By Distribution Channel
Chapter 15 Competition Landscape
   15.1 Idiopathic Gastroparesis Drugs Market: Competitive Dashboard
   15.2 Global Idiopathic Gastroparesis Drugs Market: Market Share Analysis, 2021
   15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      15.3.1 EVOKE PHARMA
      15.3.2 Cadila Pharmaceuticals
      15.3.3 Janssen-Cilag Pty Limited
      15.3.4 Abbott
      15.3.5 ADVANZ PHARMA
      15.3.6 iNova Pharmaceuticals
      15.3.7 ANI Pharmaceuticals, Inc.
      15.3.8 AstraZeneca
      15.3.9 Intas Pharmaceuticals Ltd.
      15.3.10 Cipla Inc.

Methodology

Purchase Premium Report

Buy Now

Request For Sample

Request For Customization

Enquiry Before Buying

Speak With Analyst

Customize This Report

Ask for Research To Be Focused On Specific Regions or Segments
Receive Data As Per Your Format and Definition
Companies Profiled based on Your Requirements
Breaking Down Competitive Landscape as per Your Requirements
Any Level of Customization

Our Clients

Client Testinomials

We needed a highly accurate and precise report, which Growth Market Reports delivered promptly. The company compiled information from a wide array of reliable agencies and sourcess.It is extremely satisfactory to be working with you.
Strategy Head of Major Tech Company

We were very pleased to contact Growth Market Reports as they tailored reports precisely as per our requirements. As we are dealing with the aerospace and defense industry, we need reports of high accuracy and substantial quality.
Major Player in Defense Industry

Extremely delighted to have a well-crafted report on “Global Packaging Solutions Market Research Report” from your team. Thank you for providing me with all our requirements and for incorporating our suggestions.
CMO of Leading Packaging Company from USA

I had a good experience working with Growth Market Reports as they were very open to all constructive changes in the report. I found that the report had its charm embedded with ample of data.
Founder and Managing Partner of Major Korean Company

Our company has been working with Growth Market Reports for some years now and we are very happy with the quality of the reports provided by the company.I, on behalf of my organization, would like to thank you for offering professional reports.
Global Consulting Firm

Quick Contact

+1 909 414 1393

sales@growthmarketreports.com

Growth Market Report

Certified By

FAQ Section

Some frequently asked questions about this report!

1. Can I ask for different company profiles?

Additional company profiles are provided on request. For a discussion related to the above findings, click Speak to Analyst

2. What are the criteria used for selecting a company profile?

Factors such as competitive strength and market positioning are key areas considered while selecting companies to be profiled.

3. What are the factors driving the idiopathic gastroparesis drugs market?

Increasing prevalence of gastroparesis and rising approval of medications with different routes of administration are driving the idiopathic gastroparesis drugs market.

4. How big will be the idiopathic gastroparesis drugs market in 2030?

According to this Growth Market Reports report, the idiopathic gastroparesis drugs market is anticipated to register a CAGR of 4.1% during the forecast period, 2022-2030, with an anticipated valuation of USD 1,956.5 Million by the end of 2030.

5. What are the major distribution channels of idiopathic gastroparesis drugs?

Hospital pharmacies and retail pharmacies are the major distribution channels of idiopathic gastroparesis drugs.

6. Which macroeconomic factors affect the market?

Factors such as government regulations and R&D activities are expected to act as macroeconomic factors for the market.

7. Who are the major players operating in the market?

Major manufacturers include AbbVie Inc., Janssen Biotech, Inc., Amgen Inc., AstraZeneca, Lilly, Merck & Co., Inc., Abbott, Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited.

8. What is the impact of COVID-19 on the overall market during 2019 -2020?

Demand for and supply of idiopathic gastroparesis drugs were slightly negatively affected during the pandemic, due to the scarcity of treatment processes.

9. What additional data analysis is available in a report?

In addition to market size (in US$ Million), the company market share (in % for the base year 2021), impact of key regulations, latest trends in treatment method, overview, product innovation in idiopathic gastroparesis drugs market, long-term market trends & opportunities, and scale of new market entrants are provided.

10. What is the base year calculated in the global idiopathic gastroparesis drugs market report and what is the analysis period?

The base year considered for the global idiopathic gastroparesis drugs market report is 2021. The complete analysis period is 2015 to 2030, wherein, 2015 and 2020 are the historic years, and the forecast is provided from 2022 to 2030.